A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors

NCT03497429 | Completed Phase 1 Results FDA Drug

• 3 other identifiers: Niraparib-1001U1111-1209-0340JapicCTI-183911
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese participants with advanced solid tumors.

Conditions

Advanced Solid Tumors

Keywords

Drug Therapy

Outcome Measures

Primary Outcomes (5)

• Number of Participants With Dose Limiting Toxicities (DLTs)

  DLT was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.03 and defined as any of the following events occurring during Cycle 1 that were considered by investigator to be related with niraparib: Any Grade 5 or 4 hematologic toxicity, except Grade 4 neutropenia less than (\<) 7 days; Grade 3 or 4 neutropenia with fever greater than (\>) 38.5 degree Celsius and/or infection requiring antibiotic/anti-fungal treatment; Any Grade 3, 4,or 5 non-hematologic toxicity except: Grade 3 nausea, vomiting, diarrhea/dehydration occurring in setting of inadequate compliance with supportive care and lasting \<48 hours, Inadequately treated hypersensitivity reactions, Grade 3 acidosis/alkalosis that responded to intervention by improving to less than or equal to (\<=) Grade 2 within 48 hours, Isolated asymptomatic Grade 3 amylase elevation, hypercholesterolemia and hypertriglyceridemia; Any TEAE leading to an interruption of niraparib for \>14 days.

  Baseline up to Day 21 in Cycle 1 (Cycle length=21 days)

• Number of Participants With Treatment-emergent Adverse Events (TEAEs)

  From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)

• Number of Participants With Grade 3 or Higher TEAEs

  TEAEs were graded as per the NCI-CTCAE version 4.03. As per the NCI-CTCAE, Grade 1 (mild, asymptomatic or mild symptoms); Grade 2 (moderate, minimal, local or noninvasive intervention indicated); Grade 3 (severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (life-threatening consequences, urgent intervention indicated); Grade 5 (death related to adverse event \[AE\]).

  From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)

• Number of Participants With Serious TEAEs

  From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)

• Number of Participants Who Discontinued Study Drug Due to TEAEs

  From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)

Secondary Outcomes (3)

• Cmax: Maximum Observed Plasma Concentration for Niraparib

  Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)

• Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib

  Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)

• AUC24：Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib

  Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)

Study Arms (2)

Cohort 1: Niraparib 200 mg

EXPERIMENTAL

Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.

Drug: Niraparib

Cohort 2: Niraparib 300 mg

EXPERIMENTAL

Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.

Drug: Niraparib

Interventions

Niraparib DRUG

Niraparib capsule

Cohort 1: Niraparib 200 mg; Cohort 2: Niraparib 300 mg

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Japanese male or female participants aged 20 years or older on the day of signing informed consent.
• Participants must have a cytologically- or histologically-confirmed metastatic or locally advanced solid tumor and have failed or progressed after standard therapy, or for which standard therapy does not exist in the opinion of the investigator.
• Participants must have Performance Status of less than or equal to (\<=) 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale.
• Participants must have adequate organ function as indicated by the following laboratory values:
• Hematology
• Absolute neutrophil count: greater than or equal to (\>=) 1500 per microliter (μL)
• Platelet count: \>=100,000/μL
• Hemoglobin: \>=9 gram per deciliter (g/dL)
• Kidney
• \- Serum creatinine: \<=1.5\*institutional upper limit of normal (ULN), OR creatinine clearance of \>=50 milliliter per minute (mL/min) (as calculated using the Cockcroft Gault equation or measured using 24-hour urine creatinine clearance) for participants with creatinine levels \>=1.5\*institutional ULN.
• Liver
• Total bilirubin in serum: \<=1.5\*ULN (except in participants with Gilbert's syndrome). Participants with Gilbert's syndrome may be enrolled if the participant's direct bilirubin is \<=1.5\*ULN of the direct bilirubin.
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): \<=2.5\*ULN OR \<=5\*ULN if participants have liver metastases.
• Coagulation (does not pertain to participants receiving anticoagulants)
• Prothrombin time (PT): \<=1.2\*ULN

You may not qualify if:

• Participant who have received chemotherapy, radiotherapy, hormonal or biological therapy within 14 days (within 28 days for anticancer monoclonal antibody, within 42 days for nitrosoureas or mitomycin C) prior to Cycle 1 Day 1. If the participant has residual toxicity from prior chemotherapy treatment, such toxicity must be \<=Grade 1 (NOTE: participants with Grade 2 alopecia may qualify for this study). If bevacizumab had been used in the past, all bevacizumab-related toxicities must have resolved. Participants with prostate cancer may have been treated with luteinizing hormone-releasing hormone (LH-RH) analogs.
• Participants who received a known or putative poly (ADP-ribose) polymerase (PARP) inhibitor or other drugs that may inhibit the PARP, either as part of a clinical trial or as standard of care.
• Participants who initiated bisphosphonate therapy or are adjusting bisphosphonate dose/regimen within 30 days prior to Cycle 1 Day 1. Participants on a stable bisphosphonate regimen are eligible and may continue the treatment.
• Treatment with any investigational products within 28 days or 5 half-lives (whichever was longer) before Cycle 1 Day 1.
• Participants who have symptomatic ascites or a symptomatic pleural effusion. A participant who is treated and clinically stable for these conditions is eligible.
• Participants with a known primary central nervous system (CNS) tumor.
• Participants with known CNS metastases and/or carcinomatous meningitis are excluded. However, participants with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 30 days prior to Cycle 1 Day 1 defined as: (1) no evidence of new or enlarging CNS metastases, (2) off steroids, or (3) on a stable dose and administration of steroids.
• Participants who have a hypersensitivity to the components of the study drugs or their analogs.
• Participants who are considered to be at high medical risk due to a serious, uncontrolled disease, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days prior to Cycle 1 Day 1) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, or any psychiatric disorder that prohibits obtaining informed consent.
• Participants who have a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the participant's participation throughout the study period, or study participation is not in the best interest of the participant.
• Known gastrointestinal (GI) disease or GI surgery that could interfere with the GI absorption of study drug, such as difficulty swallowing capsules and total gastrectomy.
• Participants who have a psychiatric disorder that may interfere with the conduct of the trial.
• Participant is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the past year) of drug or alcohol abuse.
• Participants who are pregnant or breast-feeding, or expecting to conceive or be a father of children within the planned duration of the study.
• NOTE: If a breast-feeding woman discontinue breast-feeding, she may be enrolled in the study.

Sponsors & Collaborators

• Takeda: lead

Study Sites (1)

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

Location

MeSH Terms

Interventions

niraparib

Results Point of Contact

• Title: Study Director
• Organization: Takeda

TrialDisclosures@takeda.com

+1-877-825-3327

Study Officials

• Study Director

  Takeda

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 5, 2018
• First Posted: April 13, 2018
• Study Start: April 5, 2018
• Primary Completion: February 10, 2020
• Study Completion: February 10, 2020
• Last Updated: November 9, 2021
• Results First Posted: November 9, 2021

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

JP (1)